Mereo BioPharma (MREO) Cash & Equivalents (2017 - 2026)

Mereo BioPharma (MREO) has reported Cash & Equivalents for 10 consecutive years, with $36.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 42.04% year-over-year to $36.2 million; the TTM figure through Mar 2026 stood at $36.2 million (down 42.04% YoY), while the FY2025 annual figure was $41.0 million, down 41.27% from the prior year.
• Cash & Equivalents slipped to $36.2 million in Q1 2026 per MREO's latest filing, from $41.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $96.2 million in Q2 2022 and bottomed at $36.2 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $61.8 million across 5 years, with a median of $57.4 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 48.02% — and 2024, when it jumped 65.91%.
• Mereo BioPharma's Cash & Equivalents stood at $66.1 million in 2022, then slipped by 13.1% to $57.4 million in 2023, then gained by 21.56% to $69.8 million in 2024, then sank by 41.27% to $41.0 million in 2025, then fell by 11.63% to $36.2 million in 2026.
• Business Quant data shows MREO's Cash & Equivalents at $36.2 million in Q1 2026, $41.0 million in Q4 2025, and $48.7 million in Q3 2025.